期刊文献+

^18F-FDG PET/CT代谢参数评估食管癌新辅助放化疗效果 被引量:2

原文传递
导出
摘要 食管癌新辅助放化疗后组织病理反应程度能预测患者远期生存,指导调整后续治疗方案.^18F-FDG PET/CT能够通过代谢变化评估肿瘤组织病理反应,具体参数包括治疗后SUV、治疗前后SUV降低百分比(△SUV%),以及治疗前后肿瘤长度变化百分比(△L%)等.目前哪项参数在预测食管癌放化疗后组织病理反应中最有效尚无定论.本研究通过观察各参数预测食管癌组织病理反应的精确性,以及代谢反应和组织病理学反应分层的生存率曲线差异情况,寻求最佳预测参数.
出处 《中华核医学与分子影像杂志》 CSCD 北大核心 2014年第5期407-408,共2页 Chinese Journal of Nuclear Medicine and Molecular Imaging
  • 相关文献

参考文献3

二级参考文献36

  • 1贾丽,于金明,王仁本,巩合义,李金丽,焦玉红.^(18)F-FDG PET/CT对乳腺癌新辅助化疗疗效预测的价值[J].中国肿瘤临床与康复,2006,13(3):215-218. 被引量:10
  • 2袁双虎,于金明,于甬华,杨新华,付政,杨国仁,郭洪波,王晓航,周英智,陈少卿.^(18)F-脱氧葡萄糖PET-CT检测食管癌病变长度的临床价值[J].中华放射肿瘤学杂志,2006,15(5):389-392. 被引量:45
  • 3邢军,李建彬,刘娟,卢洁,范廷勇,邵倩.PET-CT图像融合在食管癌精确放疗中的应用[J].实用癌症杂志,2007,22(3):290-292. 被引量:9
  • 4郭洪波,于金明,张百江,杨国仁,付政,张为迪,黄勇,刘聿辉.^(18)F-FDG PET/CT显像对食管癌原发灶长度的测量[J].中华核医学杂志,2007,27(3):185-186. 被引量:6
  • 5Thompson WM,Halvorsen RA,Foster WL Jr,et al.Computed tomography for staging esophageal and gastroesophageal cancer:reevaluation.AJR Am J Roentgenol,1983,141:951-958.
  • 6Picus D,Balfe M,Koehler RE,et al.Computed tomagraphy in the staging of esophageal carcinoma.Radiology,1983,146:433-438.
  • 7刘泰福.现代放射肿瘤学.上海:上海医科大学出版社,2008.
  • 8Takashima S,Takeuchi N,Shiozaki H,et al.Carcinoma of the osophagus:CT vs MR imaging in determining resectability.AJR Am J Roentgenol,1991,156:297-302.
  • 9麻国新,万钧.早期食管癌的放射治疗//万钧,韩春,刘惠明.食管癌的放射治疗.2版.北京:原子能出版社,2006:161-166.
  • 10Kamangar F, Dores GM, Anderson WF. Patterns of cancer inci- dence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol, 2006, 24: 2137-2150.

共引文献266

同被引文献22

  • 1刘俊,吕长兴,王家明.同步放化疗治疗不能手术的食管癌临床结果[J].中华放射肿瘤学杂志,2006,15(3):185-187. 被引量:89
  • 2Nguyen NP, Kratz S, Chi A, et al. Feasibility of image-guidedradiotherapy and concurrent chemotherapy for locally advancednonsmall cell lung cancer[J]. Cancer Invest, 2015, 33(3): 53-60.
  • 3Ogasawara N, Tamura Y, Funaki Y, et al. Rapidly growingesophageal carcinosarcoma reduced by neoadjuvant radiotherapy alone[J]. Case Rep Gastroenterol, 2014, 8(2): 227-234.
  • 4Chen WW, Wang F, Chen S, et al. Detailed analysis of prognosticfactors in primary esophageal small cell carcinoma[J]. Ann ThoracSurg, 2014, 97(6): 1975-1981.
  • 5Zhao H, Zhu W, Xie P, et al. A phase I study of concurrentchemotherapy and thoracic radiotherapy with oral epigallocatechin-3-gallate protection in patients with locally advanced stage Ⅲnon-small-cell lung cancer[J]. Radiother Oncol, 2014, 110(1):132-136.
  • 6Zhu ZF, Ma HL, Fan M, et al. Sequential chemoradiotherapy withaccelerated hypofractionated radiotherapy compared to concurrentchemoradiotherapy with standard radiotherapy for locally advancednon-small cell lung cancer[J]. Technol Cancer Res Treat, 2014, 13(3):269-275.
  • 7Hou X, Wei JC, Wu JX, et al. Multidisciplinary modalities achieveencouraging long-term survival in resectable limited-diseaseesophageal small cell carcinoma[J]. PLoS One, 2013, 8(7): 259-260.
  • 8李增智,李宁,毛晓红,杨杰,宋丽阳,张继国.替加氟对中晚期食管癌放疗增敏效果及副作用观察[J].齐鲁医学杂志,2012,27(6):485-486. 被引量:5
  • 9陆向东,张汀荣.新辅助放化疗联合手术治疗局部晚期食管癌的临床观察[J].江苏医药,2014,40(16):1936-1938. 被引量:9
  • 10任伟,闫婧,钱晓萍,刘宝瑞.食管癌放化疗后近期疗效评价标准的研究进展[J].中华肿瘤杂志,2014,36(9):641-644. 被引量:23

引证文献2

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部